An ASX-listed medical marijuana company says is providing cannabis to nearly 2,000 Australian patients with debilitating conditions, numbers it expects to more than double by year-end. Melbourne-based Althea says 1,925 patients have been prescribed with its cannabis products in Australia, and it is adding about 18 new patients per day. Chief executive Josh Fagan expects the company to have between 4,000 to 5,000 patients by year end. “The patient numbers are starting to get serious,” he said. “We think Australia has the potential to have 250,000 eligible patients in three to four years, even with the difficult regulatory framework we work in.” Getting doctors on board is the biggest hurdle, Mr Fagan said, as they need to either be approved as an authorised prescriber or must submit each prescription to the government for approval under a legal framework for medical cannabis created in October 2016. The Department of Health’s […]